Modulating Bcl-6 and AID to Extend Plasmablast Life Span
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for in vitro production of antibodies from human B-cells are limited by the inability to generate long-term antigen-specific BCR-positive cell lines, as they differentiate into terminally arrested plasma cells, preventing the production of high-affinity antibodies.
Innovation Solution
Modulating the expression of Bcl-6 and anti-apoptotic nucleic acids, such as Bcl-xL, in memory B-cells to generate antibody-producing plasmablast-like cells, while reducing the functional activity of AID to control somatic hypermutations, thereby extending the replicative life span and maintaining antibody production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If B-cells are cultured in vitro under conditions mimicking GC reaction (activation with CD40L and cytokines like IL-4, IL-10, IL-21), then antibody secretion is enhanced and differentiation to plasma cells occurs, but the cells eventually differentiate into terminally differentiated plasma cells with cell cycle arrest, precluding long-term antigen-specific BCR positive cell line generation
Solution Approach 1:
The patent applies parameter changes by modulating the expression levels of specific genes (Bcl-6, Bcl-xL, Mcl-1, AID) to control B-cell differentiation and proliferation. By adjusting the expression parameters of these key regulatory molecules, the system maintains B-cells in a productive but non-terminal state, enabling long-term antibody secretion without complete differentiation to plasma cells.
Solution Approach 2:
The invention implements dynamics by creating a balanced, dynamic equilibrium between proliferation and differentiation signals. The system continuously adjusts the expression of anti-apoptotic genes and differentiation regulators to maintain B-cells in a transient plasma cell-like state that can both divide and secrete antibodies, rather than allowing static terminal differentiation.
2Reliability
If AID functional activity is high in B-cells, then somatic hypermutations occur enabling affinity maturation, but excessive somatic hypermutations can lead to loss of antigen specificity and reduced antibody quality
Solution Approach 1:
The patent implements feedback control by monitoring and regulating AID expression levels in response to antibody affinity maturation needs. The system allows controlled somatic hypermutations through regulated AID activity, then suppresses further mutation when desired affinity is achieved, preventing excessive mutations that would compromise antigen specificity while still enabling affinity improvement.
Data Source
AI summary
The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.